Neovacs, a biotech company, develops several therapeutic vaccines for the treatment of AIDS, cancer and auto-immune and allergic diseases.
Neovacs, a spin-off from the Pierre & Marie Curie University in Paris, was founded on 1993 by Professor Daniel Zagury, one of France's most eminent immunologists and AIDS experts. Neovacs holds a broad patent portfolio and is developing several therapeutic vaccines for the treatment of AIDS, cancer and auto-immune & allergic diseases. Neovacs is acknowledged as a pioneer in the development of novel therapeutic vaccines against human cytokines (kinoids) and immunosuppressive viral proteins (toxoids). At present, monoclonal antibodies arewidely used to neutralize cytokines and treat patients suffering from cytokine-related diseases. In contrast to exogenous therapies with monoclonal antibodies, Neovacs' therapeutic vaccines induce a powerful, natural polyclonal antibody response in the patient.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Jun 22, 2021 | Post-IPO Debt | €4M | — | — | — | Detail |
Feb 8, 2021 | Post-IPO Debt | €1M | 1 | — | — | Detail |
Jul 31, 2017 | Post-IPO Equity | €6M | — | — | — | Detail |
Jan 6, 2016 | Post-IPO Equity | €5M | 1 |
![]() |
— | Detail |
Jun 29, 2015 | Post-IPO Equity | €7.50M | — | — | — | Detail |
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
---|---|---|---|---|
Oct 20, 2021
|
Series A | €1.30M | Medical | Yes |
Sep 27, 2021
![]() |
Series Unknown | $5M | Biotechnology | Yes |
Investor Name | Lead Investor | Funding Round |
---|---|---|
![]() |
Yes | Post-IPO Equity |
![]() |
Yes | Series Unknown |
![]() |
Yes | Series Unknown |
![]() |
— | Post-IPO Debt |
![]() |
— | Series Unknown |
Neovacs has had 1 exits. Neovacs most notable exits include Bio-Detection K9
Date | Company Name | Exit Type | Industry | |
---|---|---|---|---|
Sep 30, 2021 | Bio-Detection K9 | M&A | Biotechnology | Detail |